Regeneron to Collaborate on Gene Editing Therapies With Doudna-founded Mammoth
Cathie Wood's Latest Stock Portfolio: Top 10 Stock Picks
CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
ZUG, Switzerland and BOSTON, April 22, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious di
3 Cathie Wood Stocks Analysts Like Better Than Tesla
CRISPR Therapeutics Stock (NASDAQ:CRSP) Pushes Lower, But Fundamentals Are Intact
ChatGPT Stock Predictions: 10 Stocks That Have 10X Potential
Crispr Therapeutics Is Maintained at Buy by Citigroup
Crispr Therapeutics Is Maintained at Buy by Citigroup
Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $89
Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics with a Buy and raises the price target from $88 to $89.
CRISPR Therapeutics(CRSP.US) Officer Sells US$1.17 Million in Common Stock
$CRISPR Therapeutics(CRSP.US)$ Officer Kulkarni Samarth sold 19,582 shares of common stock on Apr 15, 2024 at an average price of $59.9138 for a total value of $1.17 million.Source: Announcement What
Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing
Samarth Kulkarni, Director, Chief Executive Officer, on April 15, 2024, sold 19,582 shares in Crispr Therapeutics (CRSP) for $1,173,232. Following the Form 4 filing with the SEC, Kulkarni has control
Bullish Trendline Has Never Failed Crispr Therapeutics Stock
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
Estimating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Key Insights Using the 2 Stage Free Cash Flow to Equity, CRISPR Therapeutics fair value estimate is US$68.64 Current share price of US$58.72 suggests CRISPR Therapeutics is potentially trading close
TD Cowen Says Sickle Cell Therapies May Get Higher CMS Payments
Form 144 | CRISPR Therapeutics(CRSP.US) Officer Proposes to Sell 1.17 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 15, $CRISPR Therapeutics(CRSP.US)$ Officer SAMARTH KULKARNI intends to sell 19,582 shares of its common stock on Apr 15, with a total market value of approximately $1.17 mi
Vertex Pharmaceuticals Seeks a Second Act With $4.9B Deal to Buy Alpine Immune -- Barrons.com
By Josh Nathan-Kazis While it's been said there are no second acts in American life, there can be in American biotech. Vertex Pharmaceuticals is taking a big swing to secure its own second act: Late
Needham: Reiterated CRISPR Therapeutics (CRSP.US) rating, adjusted from buy to buy rating, target price of $90.00.
Needham: Reiterated CRISPR Therapeutics (CRSP.US) rating, adjusted from buy to buy rating, target price of $90.00.
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $90 Price Target
Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $90 price target.
CRISPR Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/11/2024 45.44% Needham → $90 Reiterates Buy → Buy 03/06/2024 59.99% Mizuho $82 → $99 Maintains Buy 02/2
CRISPR Therapeutics AG (CRSP) Annual Needham Virtual Healthcare Conference - (Transcript)
CRISPR Therapeutics AG (CRSP) Annual Needham Virtual Healthcare Conference - (Transcript)
No Data